Rituximab administration following autologous stem cell transplantation for multiple myeloma is associated with severe IgM deficiency.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D018952:Antigens, CD34 / Q000096:biosynthesis; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007075:Immunoglobulin M / Q000172:deficiency* / Q000378:metabolism; D009101:Multiple Myeloma / Q000628:therapy*; D000069283:Rituximab; D013997:Time Factors; D014182:Transplantation, Autologous / Q000379:methods*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018952:Antigens, CD34; D000970:Antineoplastic Agents; D007075:Immunoglobulin M; D000069283:Rituximab; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide